Common name: European vervain
Botanical name: Verbena officinalis
© Martin Wall
Parts used and where grown
The most commonly used species is European vervain (Verbena officinalis), though
blue vervain (V. hastata) and V. macdougalii, among others, are probably
interchangeable. V. officinalis is native to Europe, Asia, and Africa and has spread
to North America. Other medicinal species are native to North America. The leaf and flower are
used in herbal medicine.
Vervain has been used in
connection with the following conditions (refer to the individual
health concern for complete information):
Historical or traditional use (may
or may not be supported by scientific studies)
Due to its bitter taste, herbalists used vervain to improve digestion. Vervain was also
used to treat people with depression and
spastic pains in the gastrointestinal tract, as a mild diaphoretic (to induce sweating and
promote mild fevers), and for all manner of female reproductive system problems when
associated with melancholy or anxiety.1 Early 20th century Eclectic physicians
(doctors who recommended herbal medicines) in the United States felt vervain might be helpful
for mild digestive problems.2
Vervain also has a reputation as a traditional remedy for stimulating production of breast
milk.3
Active constituents
The active constituents of vervain have not been thoroughly demonstrated. Glycosides, such
as verbenalin and aucubin, and a volatile oil may all contribute to its activity.4
No human studies have documented the use of this herb for any condition.
How much is usually taken?
A tea of vervain leaves and flowers is prepared by adding 1–2 teaspoons (2–4
grams) to a pint (500 ml) of hot water which is left to steep, covered, for 10–15
minutes.5 Three cups (750 ml) per day are typically recommended by doctors. The
taste of the tea is fairly disagreeable, therefore, most people prefer a tincture. Tincture,
1–2 teaspoons (5–10 ml) three times per day, is also suggested.6
Are there any side effects or interactions?
No adverse effects of vervain have been reported. Vervain should be avoided during pregnancy.7 Although, traditionally, its
use was during the last two weeks of pregnancy to facilitate labour. Vervain should be used
during pregnancy only under the guidance of a healthcare professional experienced in herbal
medicine.
At the time of writing, there were no well-known drug interactions
with vervain.
References
(To view, roll mouse over heading; to hide, click on heading)
1. Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide
for Health-Care Professionals. London: The Pharmaceutical Press, 1996, 263.
2. Felter HW. Eclectic Materia Medica, Pharmacology and
Therapeutics. Sandy, OR: Eclectic Medical Publications, 1922, 693–4.
3. Oliver-Bever BEP. Medicinal Plants in Tropical West Africa.
Cambridge: Cambridge University Press, 1986.
4. Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide
for Health-Care Professionals. London: The Pharmaceutical Press, 1996, 263.
5. British Herbal Medicine Association. British Herbal
Pharmacopoeia. West York, UK: BHMA, 1983.
6. British Herbal Medicine Association. British Herbal
Pharmacopoeia. West York, UK: BHMA, 1983.
7. McGuffin M, Hobbs C, Upton R, Goldberg A (eds). American Herbal
Products Association’s Botanical Safety Handbook. Boca Raton, FL: CRC Press,
1997.
Copyright © 2006 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the
company.
Learn more about the authors of
Healthnotes.
The information presented in Healthnotes is for informational purposes
only. It is based on scientific studies (human, animal, or in vitro), clinical
experience, or traditional usage as cited in each article. The results reported may not
necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over the counter medication is also available. Consult your doctor,
practitioner, and/or chemist for any health problem and before using any supplements or before
making any changes in prescribed medications. Information expires March 2007.